NervGen Pharma Corp.

Recent News

• NervGen Pharma Grants Stock Options

  Vancouver, Canada--(Newsfile Corp. - February 23, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the Company has granted 285,000 incentive stock options to directors of the Company and 10,000 incentive stock options to existing consultants providing investor relations services exercisable at a price of $1.94 per share for a period of five years and that vest...

  2023-02-23 6:03 PM EST
• NervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291

  Completed NVG-291 dosing of subjects in Phase 1 clinical trialPhase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury planned to start in Q3 2023NVG-291 has been demonstrated in preclinical studies to promote repair mechanisms in the nervous system, including axonal regeneration, remyelination and plasticity Vancouver, British Columbia--(Newsfile Corp. - February 14, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for...

  2023-02-14 8:30 AM EST
• NervGen Pharma Announces Composition of Matter Patent for NVG-291 Granted by the US Patent and Trade Office

  Vancouver, British Columbia--(Newsfile Corp. - November 17, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the US Patent and Trade Office (USPTO) has issued US Patent No. 11,497,812 B2 Compositions and Methods for Inhibiting the Activity of LAR Family Phosphatases to Case Western Reserve University. NervGen has an exclusive worldwide license to this patent and related...

  2022-11-17 8:30 AM EST
• NervGen Pharma Grants Stock Options

  Vancouver, British Columbia--(Newsfile Corp. - November 15, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the Company has granted 400,000 incentive stock options to directors of the Company exercisable at a price of $1.74 per share for a period of five years and that vest equally every three months over a one-year period. All options have...

  2022-11-15 7:16 PM EST
• NervGen Pharma Completes Dosing in Its Third Multiple Ascending Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q3 2022 Results

  Dosing completed in third dose cohort of multiple ascending dose (MAD) portion of Phase 1 clinical trial in postmenopausal femalesU.S. Food and Drug Administration (FDA) amendment of partial clinical hold allows for bridging cohorts of males and premenopausal females in the Phase 1 trial to commenceGlenn Ives appointed as Lead Independent DirectorVancouver, British Columbia--(Newsfile Corp. - November 14, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative...

  2022-11-14 8:30 AM EST
• NervGen Engages Cloutier Consulting to Provide Media Relations Services

  Vancouver, British Columbia--(Newsfile Corp. - October 31, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that it has engaged Cloutier Consulting, a Texas based public relations specialty agency, to provide media relations and related services for the Company.Cloutier Consulting was engaged for an initial term of one year. Cloutier Consulting will receive cash compensation that is paid...

  2022-10-31 12:00 PM EDT
• NervGen Pharma Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291

  Dose(s) to be tested in bridging cohorts of males and premenopausal females resulted in significant functional improvements in animal models of nervous system damageNervGen has completed enrollment of third and final multiple ascending dose cohort of postmenopausal womenVancouver, British Columbia--(Newsfile Corp. - October 25, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the repair of nervous system damage, announced that the U.S. Food and...

  2022-10-25 7:30 AM EDT
• NervGen Pharma Presenting at Upcoming Scientific Meetings

  AMERICAN NEUROLOGICAL ASSOCIATION ANNUAL MEETINGEUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS Vancouver, British Columbia--(Newsfile Corp. - October 20, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will be presenting posters at two upcoming scientific meetings - the 147th American Neurological Association (ANA) annual meeting on October 22-25, 2022, and the 38th Congress of the European Committee...

  2022-10-20 8:30 AM EDT
• NervGen Pharma Awarded up to $1.5 Million US Department of Defense Funding to Evaluate NervGen's NVG-291-R for Peripheral Nerve Injury

  The $1.5 million award is to evaluate the ability of NervGen's NVG-291-R to accelerate and enhance restoration of function following peripheral nerve injury (PNI)The research is to support a potential game changing therapeutic approach to restore function for US military service members and the estimated 20+ million Americans suffering from PNI There are currently no effective regenerative pharmaceuticals to enhance recovery in PNI Vancouver, British Columbia--(Newsfile Corp. - October 12, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen"...

  2022-10-12 8:30 AM EDT
• NervGen Pharma Announces Results of Annual General Meeting of Shareholders

  All resolutions submitted for approval were passed by shareholdersVancouver, British Columbia--(Newsfile Corp. - September 29, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announces the results of its Annual General Meeting of Shareholders ("AGM") held on September 28, 2022. "We appreciate the support from our shareholders demonstrated at this AGM," stated Bill Radvak, NervGen's Executive Chairman and Interim CEO. "With our Phase...

  2022-09-29 8:30 AM EDT